Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jul 14;12(26):4130-6.
doi: 10.3748/wjg.v12.i26.4130.

Alphastatin downregulates vascular endothelial cells sphingosine kinase activity and suppresses tumor growth in nude mice bearing human gastric cancer xenografts

Lin Chen  1 , Tao Li, Rong Li, Bo Wei, Zheng Peng
Affiliations

Alphastatin downregulates vascular endothelial cells sphingosine kinase activity and suppresses tumor growth in nude mice bearing human gastric cancer xenografts

Lin Chen et al. World J Gastroenterol. .

Abstract

Aim: To investigate whether alphastatin could inhibit human gastric cancer growth and furthermore whether sphingosine kinase (SPK) activity is involved in this process.

Methods: Using migration assay, MTT assay and Matrigel assay, the effect of alphastatin on vascular endothelial cells (ECs) was evaluated in vitro. SPK and endothelial differentiation gene (EDG)-1, -3, -5 mRNAs were detected by reverse transcription-polymerase chain reaction (RT-PCR). SPK activity assay was used to evaluate the effect of alphastatin on ECs. Matrigel plug assay in nude mice was used to investigate the effect of alphastatin on angiogenesis in vivo. Female nude mice were subcutaneously implanted with human gastric cancer cells (BGC823) for the tumor xenografts studies. Micro vessel density was analyzed in Factor VIII-stained tumor sections by the immunohistochemical SP method.

Results: In vitro, alphastatin inhibited the migration and tube formation of ECs, but had no effect on proliferation of ECs. RT-PCR analysis demonstrated that ECs expressed SPK and EDG-1, -3, -5 mRNAs. In vivo, alphastatin sufficiently suppressed neovascularization of the tumor in the nude mice. Daily administration of alphastatin produced significant tumor growth suppression. Immunohistochemical studies of tumor tissues revealed decreased micro vessel density in alphastatin-treated animals as compared with controls.

Conclusion: Downregulating ECs SPK activity may be one of the mechanisms that alphastatin inhibits gastric cancer angiogenesis. Alphastatin might be a useful and relatively nontoxic adjuvant therapy in the treatment of gastric cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Alphastatin inhibit HUVECs migration induced by HGF( crystatl violet stain, × 100). All data shown as mean ± SD. aP < 0.05; bP < 0.01 vs control group.
Figure 2
Figure 2
Alphastatin has no effect on HUVECs proliferation.
Figure 3
Figure 3
Alphastatin inhibit HUVECs tubule formation in response to PMA. All data shown as mean ± SD. aP < 0.05 vs control group.
Figure 4
Figure 4
Expression of SPK , EDG-1, EDG-3, EDG-5 in HUVECs.
Figure 5
Figure 5
Alphastatin downregulate HUVECs SPK activity in a dose-dependent manner. HUVECs SPK activity reached a minimum value at 6 h. All data shown as mean ± SD. A: aP < 0.05; bP < 0.01 vs 0 nmol/L alphastatin; B: aP < 0.05 vs 0 h group.
Figure 6
Figure 6
Alphastatin inhibit new capillaries formation on Matrigel plug (original magnification × 100). A: Many newly formed capillaries full of red blood cells (arrow); B: Granuloma formation without significant neovasculature.
Figure 7
Figure 7
Factor-VIII staining revealed decreased blood vessel density in alphastatin-treated group vs PBS group (× 400).
Figure 8
Figure 8
Animals injected with alphastatin exhibited a significantly reduced tumor volume. All data shown as mean ± SD. aP < 0.05; bP < 0.01 vs PBS group.
See this image and copyright information in PMC

References

    1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257. - PubMed
    1. Bamias A, Dimopoulos MA. Angiogenesis in human cancer: implications in cancer therapy. Eur J Intern Med. 2003;14:459–469. - PubMed
    1. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002;2:83–90. - PubMed
    1. Aoki K, Watanabe K, Sato M, Ikekita M, Hakamatsuka T, Oikawa T. Effects of rhizoxin, a microbial angiogenesis inhibitor, on angiogenic endothelial cell functions. Eur J Pharmacol. 2003;459:131–138. - PubMed
    1. Jansen M, de Witt Hamer PC, Witmer AN, Troost D, van Noorden CJ. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Brain Res Rev. 2004;45:143–163. - PubMed

MeSH terms